All News

2020

September

Media Release / Sep 11, 2020

Novartis data show early treatment with Mayzent® (siponimod) delays disability progression and show benefits in cognitive performance in patients with secondary progressive multiple sclerosis (SPMS)

Read More
Media Release / Sep 11, 2020

Novartis presents data at ACTRIMS-ECTRIMS for Kesimpta® (ofatumumab) in newly diagnosed treatment-naïve adults with relapsing multiple sclerosis

Read More
Nuclear Medicine
Story / Sep 11, 2020

Not your grandparents’ nuclear medicine

Novartis is taming nuclear power and putting it to use to treat advanced cancer.

Read More
Featured News / Sep 09, 2020

New report shows how AI in health is critical for COVID-19 response and recovery

AI offers the greatest potential to transform health systems from being reactive to proactive, predictive, and even preventive.

Read More
Media Release / Sep 08, 2020

Novartis data at ACTRIMS-ECTRIMS highlight the strength of leading multiple sclerosis (MS) portfolio with life-changing therapies for people across the MS spectrum

Read More
Man using digital tablet
Story / Sep 07, 2020

Reimagining asthma care: how data and digital could bring asthma management goals within reach

Bertrand Bodson explains the Novartis strategy for digital innovation in asthma care.

Read More
Media Release / Sep 07, 2020

Novartis post hoc analysis shows high-dose Enerzair® Breezhaler® reduces asthma exacerbations versus medium-dose, complementing key pivotal IRIDIUM study findings

Read More
Media Release / Sep 02, 2020

Novartis announces NEJM publication of pivotal study of Tabrecta™ in patients with METex14 metastatic non-small cell lung cancer

Read More
Featured News / Sep 02, 2020

AveXis renamed Novartis Gene Therapies, signifying the growing importance of gene therapy to Novartis corporate strategy

Read More
Media Release / Sep 01, 2020

New collaboration between Novartis and Africa Medical Supplies Platform to facilitate supply of COVID-19 related medicines

Read More

Related Links

Novartis Annual Reporting Suite

Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society ESG report.

Learn More